The effect of long term, low-dose tranexamic acid treatment on platelet dysfunction and haemoglobin levels in haemodialysis patients

Thrombosis and Haemostasis

Volumn 94, Issue 6, 2005, Pages 1245-1250

  Šabovič, Mišo ^a   Zupan, Irena Preložnik ^a   Salobir, Barbara ^a   Zupan, Igor ^a   Černelč, Peter ^a   Lavre, Janez ^b   Vujkovac, Bojan ^b  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^b Slovenj Gradec General Hospital   (Slovenia)

Author keywords

Haemodialysis patients; Haemoglobin; Platelet; Tranexamic acid

Indexed keywords

D DIMER; ERYTHROPOIETIN; HEMOGLOBIN; PLASMINOGEN; TRANEXAMIC ACID; VON WILLEBRAND FACTOR;

ADULT; AGED; ANEMIA; ARTERY THROMBOSIS; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; FEMALE; FIBRINOLYSIS; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEMOGLOBIN DETERMINATION; HUMAN; LONG TERM CARE; LOW DRUG DOSE; MALE; PILOT STUDY; PRIORITY JOURNAL; THROMBOCYTE DYSFUNCTION; THROMBOCYTE FUNCTION; UREMIA; VEIN THROMBOSIS;

AGED; ANTIFIBRINOLYTIC AGENTS; BLOOD PLATELETS; ERYTHROPOIETIN; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOLYSIS; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PLASMINOGEN; PLATELET FUNCTION TESTS; PROSPECTIVE STUDIES; RENAL DIALYSIS; TIME FACTORS; TRANEXAMIC ACID;

EID: 29244437827     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH05-02-0123     Document Type: Article

References (29)

1. Livio M, Marchesi D, Remuzzi G. Coagulation abnormalities in uraemia. Semin Nephrol 1985; 5: 82-90.
2. Eberst ME, Berkowitz LR. Haemostasis in renal disease: Pathophysiology and management. Am J Med 1994; 96: 168-79.
3. Rabelink TJ, Zwaginga JJ, Koomans HA et al. Thrombosis and haemostasis in renal disease. Kidney Int 1994; 46: 287-96.
4. Mezzano D, Tagle R, Panes O et al. Hemostatic disorder of uraemia: the platelet defect, main determinant of prolonged bleeding time, is correlated with indices of activation of coagulation and fibrinolysis. Thromb Haemost 1996; 76: 312-21.
5. Remuzzi G. Bleeding in renal failure. Lancet 1988; 1: 1205-8.
6. Weigert AL, Schafer AI. Uremic bleeding: pathogenesis and therapy. Am J Med Sci 1998; 316: 94-104.
7. Noris M, Remuzzi G. Uremic bleeding: closing the circle after 30 years of controversies? Blood 1999; 94: 2569-74.
8. Zupan IP, Sabovic M, Salobir B et al. Utility of in vitro closure time test for evaluating platelet-related primary haemostasis in dialysis patients. Am J Kidney Dis 2003; 42: 746-51.
9. Favaloro EJ. Utility of the PFA-100 for assessing bleeding disorders and monitoring therapy: a review of analytical variables, benefits and limitations. Haemophilia 2001; 7: 170-9.
10. Kratzer MAA, Born GVR. Platelet function defects: simulation of primary haemostasis in vitro. Haemostasis 1985; 18: 167-85.
11. Kundu SK, Heilmann EJ, Sio R et al. Description of an in vitro platelet function analyzer PFA-100. Semin Thromb Haemost 1995; 21(Suppl 2): 106-12.
12. Mammen EF, Comp PC, Gosselin R et al. PFA-100™ System: a new method for assessment of platelet dysfunction. Semin Thromb Hemost 1998; 24: 195-202.
13. Marchant KK, Corcoran G. The laboratory diagnosis of platelet disorders. An algorithmic approach. Arch Pathol Lab Med 2002; 126: 133-46.
14. Nenci GG, Berrettini M, Agnelli G et al. The effect of peritoneal dialysis, hemodialysis and kidney transplantation on blood platelet function. I. Platelet aggregation by ADP and epinephrine. Nephron 1979; 23: 287-92.
15. Remuzzi G, Livio M, Marchiaro G et al. Bleeding in renal failure: altered platelet function in chronic uraemia only partially corrected by haemodialysis. Nephron 1978; 22: 347-53.
16. George JN, Shatill SJ. The clinical importance of acquired abnormalities of platelet function. N Eng J Med 1991; 324: 27-39.
17. Kozek-Langenecker SA, Masaki T, Mohammad H et al. Fibrinogen fragments and platelet dysfunction in uraemia. Kidney Int 1999; 56: 299-305.
18. Mannucci PM. Hemostatis drugs. N Engl J Med 1998; 339: 245-53.
19. Hoylaerts M, Lijnen HR, Collen D. Studies on the mechanism of the antifibrinolytic action of tranexamic acid. Biochim Biophys Acta 1981; 673: 75-85.
20. Markus G, Priore RL, Wissler FC. The binding of tranexamic acid to native (Glu) and modified (Lys) human plasminogen and its effect on conformation. J Biol Chem 1979; 254: 1211-6.
21. Cyklokapron (Pharmacia). In: Krogh CME (ed). CPS Compendium of pharmaceuticals and specialties. 28th ed. Ottawa: Canadian Pharmaceutical Association; 1993: 311-2.
22. Mezzano D, Panes O, Munoz B et al. Tranexamic acid inhibits fibrinolysis, shortens the bleeding time and improves platelet function in patients with chronic renal failure. Thromb Haemost 1999; 82: 1250-4.
23. Wellington K, Wagstaff AJ. Tranexamic acid: a review of its use in the management of menorrhagia. Drugs 2003; 63: 1417-33.
24. Bonnar J, Sheppard BL. Treatment of menorrhagia during menstruation: randomised controlled trial of ethamsylate, mefenamic acid, and tranexamic acid. BMJ 1996; 313: 579-82.
25. Katsaros D, Petricevic M, Snow NJ et al. Tranexamic acid reduces postbypass blood use: a double blinded, prospective, randomized study of 210 patients. Ann Thorac Surg 1996; 1131-5.
26. Vujkovac B, Lavre J, Sabovic M. Successful treatment of bleeding from colonic angiodysplasias with tranexamic acid in a haemodialysis patient. Am J Kidney Disease 1998; 31: 536-8.
27. Vujkovac B, Sabovic M. Treatment of subdural and intracerebral hematomas in a haemodialysis patient with tranexamic acid. Nephrol Dialysis Transplant 2000; 15: 107-9.
28. Sabovic M, Lavre J, Vujkovac B. Tranexamic acid is beneficial as adjunctive therapy in treating major upper gastrointestinal bleeding in dialysis patients. Nephrol Dialysis Transplant 2003; 18: 1388-91.
29. Lindoff C, Rybo G, Astedt B. Treatment with tranexamic acid during pregnancies and the risk of thromboembolic complications. Thromb Haemost 1993; 70: 238-40.